Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.20 USD
+0.14 (4.58%)
Updated Jul 19, 2024 04:00 PM ET
5-Strong Sell of 5 5
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
AQST 3.20 +0.14(4.58%)
Will AQST be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AQST
New Strong Sell Stocks for July 16th
New Strong Sell Stocks for July 11th
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Small Drug Stocks to Buy From a Recovering Industry
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
Other News for AQST
Optimistic Outlook for Aquestive Therapeutics’ Anaphylm with Positive PK Results and Strategic FDA Engagement
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
Aquestive gains after initial data for allergy candidate
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film